FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
11 letters match. Newest first.
-
DrugsAmgen Inc.
FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.
Medium -
Drugs24HrDoc, Inc. dba 24HrDoc
FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.
Medium -
DrugsFWD Care, Inc. dba FWD
FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.
Medium -
DrugsAytu Biopharma
FDA says Aytu Biopharma’s sponsored links for ADHD drug Cotempla XR-ODT are false or misleading and misbrand it.
High risk -
DrugsAytu Biopharma
FDA warned Aytu Biopharma that sponsored links for ADHD drug Adzenys XR-ODT are false or misleading because they omit risk information.
High risk -
DrugsHello Cake, Inc. dba Hello Cake
FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.
Medium -
DrugsAlora Pharmaceuticals
FDA says Alora's paid search ads for RELEXXII ADHD drug are false or misleading because they omit risk information.
Low -
DrugsCurex
FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.
High risk -
DrugsEli Lilly and Company
FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.
Low -
DrugsAstraZeneca Pharmaceuticals LP
FDA says AstraZeneca's Breztri sales aid made false or misleading efficacy claims, making the COPD drug misbranded.
Low